SAB Biotherapeutics, Inc. (SABS)
Automate Your Wheel Strategy on SABS
With Tiblio's Option Bot, you can configure your own wheel strategy including SABS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SABS
- Rev/Share 0.0407
- Book/Share 2.304
- PB 0.816
- Debt/Equity 0.3169
- CurrentRatio 1.6882
- ROIC -1.4315
- MktCap 17468396.0
- FreeCF/Share -3.4026
- PFCF -0.5525
- PE -0.5096
- Debt/Assets 0.1779
- DivYield 0
- ROE -1.0514
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | SABS | H.C. Wainwright | -- | Buy | -- | $10 | May 14, 2025 |
| Initiation | SABS | Craig Hallum | -- | Buy | -- | $11 | Oct. 9, 2024 |
| Initiation | SABS | Oppenheimer | -- | Outperform | -- | $12 | Aug. 28, 2024 |
News
SAB BIO Announces Oversubscribed $175 Million Private Placement
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners Proceeds expected to fully fund completion of pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune T1D in newly diagnosed T1D patients (Stage 3) Company expects proceeds to extend cash runway into the middle of 2028 Potential for up to an additional $284 million of gross proceeds if milestone-based warrants exercised in full MIAMI, July 21, …
Read More
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments. Samuel J. Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or delay the progression of type 1 diabetes.
Read More
About SAB Biotherapeutics, Inc. (SABS)
- IPO Date 2021-02-09
- Website https://www.sabbiotherapeutics.com
- Industry Biotechnology
- CEO Samuel J. Reich
- Employees 63